Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label long-term safety and efficacy study of lanadelumab in non-histaminergic angioedema with normal C1-INH
2019-004823-20Phase 3Completed
- Sponsor
- Takeda
- Start
- Feb 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of lanadelumab in angioedema, sponsored by Takeda. Primary endpoint: Long-term safety of lanadelumab. Started Feb 2021; status: completed.
02
Drugs
lanadelumab
03
Conditions
angioedema
Beyond the preview
Go deeper on 2019-004823-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-004823-20.